Status:

COMPLETED

Bilateral DLPC tDCS in Drug-resistant Migraine

Lead Sponsor:

Clínica de Intervención en Neurociencias

Conditions:

Migraine

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to study and describe the effects of bilateral tDCS applied to dorso-lateral-prefrontal cortex (DLPC) in patients with drug-resistant migraine in terms of reduction ...

Eligibility Criteria

Inclusion

  • diagnosis of high-frequency and/or chronic migraines, according to the diagnostic criteria of the ICHD-III,
  • failure to more than 3 preventive drugs
  • stable pharmacological treatment (\> 6 months without changes),
  • absence of other neurological or medical pathological conditions,
  • written informed consent.

Exclusion

  • seizures
  • significant cognitive impairment that prevents following orders and understanding instructions (Mini-Mental State Examination \< 23)
  • pregnancy
  • aphasia or limitations in communication,
  • metallic cranial implants
  • another neurological or psychiatric pathology
  • diagnosis of another type of migraine.

Key Trial Info

Start Date :

October 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2023

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT06079801

Start Date

October 1 2021

End Date

August 31 2023

Last Update

October 17 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinica de Intervencion en Neurociencias

Talavera de la Reina, Toledo, Spain, 45600